All Updates

All Updates

icon
Filter
M&A
Lucira Health acquired by Pfizer for USD 36.4 million
Telehealth
Apr 28, 2023
This week:
M&A
N-able acquires Adlumin for USD 266 million to strengthen cybersecurity offerings
Next-gen Cybersecurity
Today
M&A
Bitsight acquires Cybersixgill for USD 115 million to enhance threat intelligence capabilities
Cyber Insurance
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Generative AI Infrastructure
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Data Infrastructure & Analytics
Today
Product updates
Microsoft launches Copilot Actions for workplace automation
Foundation Models
Yesterday
M&A
Almanac acquires Gro Intelligence's IP assets for undisclosed sum
Smart Farming
Yesterday
Partnerships
Aduro Clean Technologies partners with Zeton to build hydrochemolytic pilot plant
Waste Recovery & Management Tech
Yesterday
Funding
Oishii raises USD 16 million in Series B funding from Resilience Reserve
Vertical Farming
Yesterday
Management news
GrowUp Farms appoints Mike Hedges as CEO
Vertical Farming
Yesterday
M&A
Rise Up acquires Yunoo and expands LMS monetization capabilities
EdTech: Corporate Learning
Yesterday
Apr 28, 2023

Lucira Health acquired by Pfizer for USD 36.4 million

M&A

  • Lucira Health, a biotech company that produces disposable tests for infectious diseases, was acquired by pharma giant Pfizer for a total consideration of USD 36.4 million through a bankruptcy auction. The company filed for bankruptcy in February 2023 and had USD 146 million in assets and USD 85 million in debts, as of December 2022. The acquisition closed on April 20, 2023. 

  • The firm declared bankruptcy two days before receiving FDA Emergency Use Authorisation (EUA) for the first over-the-counter at-home test that distinguishes ARS-CoV-2 from influenza A and B.

  • Lucira Health faced financial difficulties due to the lengthy and costly EAU process, with the FDA citing a dangerous chemical in the test components as the cause of the delay. It was also affected by the decline in demand for Covid-19 testing. The acquisition by Pfizer provides a lifeline for the company and ensures the continuity of its Covid-19 testing capabilities.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.